Ocular Therapeutix (OCUL) Misses Q1 EPS by 9c

Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.38), $0.09 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $17.07 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Alpha's Drilling Confirms Second Target of Scale at Anagulu Copper-Gold Porphyry Project
• Rothschild Redburn Upgrades Apple (AAPL) to Buy